
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc is viewed positively due to its attractive current valuation, which, despite a reduction in the 12-month price target to $40 following a net present value analysis, suggests significant upside potential relative to the current share price. The company is focused on developing therapies that address serious autoimmune disorders, which are becoming increasingly relevant as evidenced by the rising incidence of idiopathic pulmonary fibrosis, with over 40,000 new cases diagnosed each year. Furthermore, GRI Bio’s unique product candidates, including GRI-0621 and GRI-0803, position the company favorably within the biotech sector, balancing high risks with substantial opportunities for growth.
Bears say
GRI Bio Inc reported a net loss of $3.9 million, equating to an earnings per share (EPS) of $(7.72), which fell short of both company estimates and consensus expectations. Significant concerns are raised regarding the company's liquidity and balance sheet, alongside multiple risks related to the clinical development of its product candidates, including the potential failure to demonstrate safety and efficacy, gain regulatory approval, or secure commercialization and reimbursement. Additionally, macroeconomic factors and shifting investor sentiment towards biotech investments further exacerbate the uncertainty surrounding GRI Bio's financial outlook.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares